About this Research Topic
While RPT biological effects are still to be fully understood, the impact of these agents has led to an exponential increase in RPT clinical trials in the last two decades. To support the need for clinical trials, the primary supply for RPT relies on the provision of therapeutic isotopes. Specifically, challenges subsidize on the large-scale supply of therapeutic isotopes and radiopharmaceutical manufacturing.
In the proposed journal collection, at Frontiers in Oncology, the editorial team intends to gather a core of reports and data supporting the communication of the most recent advancements in therapeutic isotope supply and radiopharmaceutical manufacturing for cancer care. Along with this topic, an in-depth understanding of the cancer biology utilizing those treatments will be addressed and reported over pre-clinical and clinical research articles publishing.
A binder of several research reports and opinion-piece articles will be assembled specifically dealing with the current challenges and progress in radioisotope supply and radiopharmaceutical therapy manufacturing. RPT development leading to drug agency approval will be addressed including regulatory questions, toxicological reports, dosimetry, and the current expected standards of quality attributes for RPT drugs.
This collection will present as well the most up-to-date reports in pre-clinical and clinical cancer research developments using innovative RPT treatments and investigations in patient care.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
In the proposed journal collection, at Frontiers in Oncology, the editorial team intends to gather a core of reports and data supporting the communication of the most recent advancements in therapeutic isotope supply and radiopharmaceutical manufacturing for cancer care. Along with this topic, an in-depth understanding of the cancer biology utilizing those treatments will be addressed and reported over pre-clinical and clinical research articles publishing.
A binder of several research reports and opinion-piece articles will be assembled specifically dealing with the current challenges and progress in radioisotope supply and radiopharmaceutical therapy manufacturing. RPT development leading to drug agency approval will be addressed including regulatory questions, toxicological reports, dosimetry, and the current expected standards of quality attributes for RPT drugs.
This collection will present as well the most up-to-date reports in pre-clinical and clinical cancer research developments using innovative RPT treatments and investigations in patient care.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: Therapeutic, Isotope, Supply, Radiopharmaceutical, Manufacturing, Cancer Care
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
